Disrupted genetic regulation causes common disturbance in metabolism of fat

February 06, 2008

The disease familial combined hyperlipidemia (FCH) is a common cause of disturbed metabolism of fat and early heart attacks. Uppsala University scientists have now developed a pioneering method and can show for the first time what genes are regulated by the gene USF1, which is known to cause the disease. These findings are being presented today in the leading journal Genome Research.

Familial combined hyperlipidemia is caused by the gene USF1, which in turn regulates many other genes, but until now there have been no techniques for finding which ones. Professor Claes Wadelius, at the Department of Genetics and Pathology, Uppsala University, has devised new methods for analyzing genetic regulation and found a number of genes that govern fat levels and energy conversion. The breakthrough is a result of close collaboration with Professor Jan Komorowski at the Linnaeus Center for Bioinformatics.

How active a gene is is regulated by proteins, called transcription factors, which are bound to the DNA strands. Until now, this has been analyzed in test tubes and only one gene at a time. Claes Wadelius' research team has developed new high-efficiency methods that improve the results in two crucial ways. On the one hand, living cells are now analyzed, not synthetic genes in test tubes. On the other, the entire human genome is analyzed in a single experiment, not merely a genetic fragment.

The method has been used to find genes that have a disturbed function in the common disease familial combined hyperlipidemia. These patients have elevated levels of cholesterol or other fats, which leads to increased risk of being afflicted by early hardening of the arteries and heart attack. Analyses show that the gene USF1 in turn governs the activities of more than 1,000 genes, several of which determine the body's levels of fat. It also regulates a number of genes that participate in the cell's energy production, which provides new ways of understanding disturbances in metabolism. The new methods are 10-100 million times more efficient that the old ones, and the project involved more than a billion analyses. This places great demands on how we register, store, and interpret data.

"Technological advances are making medical research more of an information science. With these precise new methods for analyzing data we have entirely new capabilities for understanding the causes of disturbances in metabolism. In other projects we are using the same methods to understand new causes of cancer," says Professor Claes Wadelius.

Uppsala University

---

---

	Hyperlipidemia: Diagnosis and Management (A Hodder Arnold Publication) by Paul N. Durrington (Author) This third edition of this well-received text continues to provide a state-of-the-art treatise on modern clinical practice relating to hyperlipidemia and lipoprotein disorders, conditions responsible for a huge amount of morbidity and mortality in Western countries and, increasingly, the developing world. The clinical evidence underlying the treatment of hyperlipidemia has burgeoned since the second edition published in 1994, with the publication of the results of many clinical trials on the new statin drugs, and teh subsequent appearance of national and international guidelines for cholesterol lowering in coronary prevention. There has also been considerable development in the definition of cardiovascular risk, and the methodology for identifying high-risk patients. All of these...
	A statin for a patient with hyperlipidemia and hepatitis C? (Postgraduate Medicine) by JTE Multimedia A 46-year-old man with newly diagnosed hepatitis C and normal transaminase levels has a low-density lipoprotein cholesterol (LDL-C) concentration of 178 mg/dL (4.60 mmol/L). Would it be appropriate to start a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor ("statin") in such a patient? Original Publication Date: May 2004
	HYPERLIPIDEMIA: Introduction to a four-article symposium (Postgraduate Medicine) by JTE Multimedia Coronary artery disease remains the No. 1 killer of both men and women in the United States. The correlation with hyperlipidemia is alarmingly clear: More than half of cases of heart disease are attributable to lipid abnormalities. The goal of this symposium is to emphasize the importance of controlling hyperlipidemia to reduce the incidence of heart disease. Original Publication Date: December 2000
	Hyperlipidemia in Primary Care: A Practical Guide to Risk Reduction (Current Clinical Practice) by Matthew J. Sorrentino (Editor) Cardiovascular disease is the number one cause of death for men and women in this country, surpassing deaths due to all cancers combined. Better awareness of heart disease risk factors and improved treatment modalities has produced great progress in reducing deaths due to myocardial infarction and stroke over the past few decades.  Still, more progress is needed, as about half of all first coronary events occur in individuals who have no cardiac symptoms and no previously diagnosed heart disease.  The primary care physician, therefore, has an important role in identifying at risk individuals and beginning preventive modalities.   In Hyperlipidemia in Primary Care: A Practical Guide to Risk Reduction, a group of leading authorities in the field offers a comprehensive overview of the...
	Hyperlipidemia Management for Primary Care: An Evidence-Based Approach by Brian V. Reamy (Editor) This book provides multifaceted strategies necessary to treat hyperlipidemia, as well as tips for incorporating techniques into clinical practice. In addition to discussing pharmacologic treatment, the book includes a review of popular diets and therapeutic foods, herbs, and vitamins. A section on evidence-based recommendations for treating special populations discusses approaches for elderly patients, women, elite athletes, and other populations with unique medical needs. Case studies illustrate the principles introduced in the book. The text is complete with screening tools for real world risk assessment.
	Drug Treatment of Hyperlipidemia (Fundamental and Clinical Cardiology) by B. Rifkind (Author)
	The Metabolic Syndrome: Diabetes, Obesity, Hyperlipidemia and Hypertension: Proceedings of the 8th European Symposium on Metabolism, Padua, Italy, 2-5 ... 2002, ICS 1253, 1e (International Congress) by Gaetano Crepaldi (Editor), Antonio Tiengo (Editor), Angelo Avogaro (Editor) This volume contains the papers presented at "The 8th European Symposium on Metabolism". It provides a comprehensive and updated evaluation of the possible role of insulin resistance in the pathogenesis of a cluster of major risk factors for cardiovascular disease. Insulin resistance was recognized as a feature and a pathogenetic mechanism in pathological states such as type 2 diabetes mellitus and obesity. More recently, however, it has become apparent that impairment in insulin action may be shared by a variety of conditions not necessarily associated with diabetes or obesity such as hypertension and endothelial dysfunction. It leads not only to metabolic but also to hemodynamic alterations and to proinflammatory reactions. Therefore, The Metabolic Syndrome is a disorder in which not...
	Hyperlipidemia - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications (Author) This is a 3-in-1 reference book. It gives a complete medical dictionary covering hundreds of terms and expressions relating to hyperlipidemia. It also gives extensive lists of bibliographic citations. Finally, it provides information to users on how to update their knowledge using various Internet resources. The book is designed for physicians, medical students preparing for Board examinations, medical researchers, and patients who want to become familiar with research dedicated to hyperlipidemia.If your time is valuable, this book is for you. First, you will not waste time searching the Internet while missing a lot of relevant information. Second, the book also saves you time indexing and defining entries. Finally, you will not waste time and money printing hundreds of web pages.
	Hyperlipidemias: Webster's Timeline History, 1967 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Hyperlipidemias," including when used in literature (e.g. all authors that might have Hyperlipidemias in their name). As such, this book represents the largest compilation of timeline events associated with Hyperlipidemias when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...
	Primary Hyperlipidemias: An Atlas Of Investigation And Diagnosis by J. Davignon (Author), R. Dufour (Author) Drawing upon a rich collection of visual material, this ground-breaking book illustrates the full range of lipid disorders and explores the different categories of both primary and secondary dyslipoproteinemias. By referring to the hundreds of high quality images included in this work, physicians will be able to confidently identify and diagnose the whole range of lipid disorders. As a visual guide to diagnosis, this atlas will assist cardiologists, endocrinologists, primary care physicians and other healthcare professionals in their daily task of making an accurate assessment, and thereafter will help to formulate the most effective program of management for each manifestation of this highly complex group of disorders.